Repligen Financial Statements
NASDAQ: RGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Repligen revenue and earnings
In fiscal 2025, Repligen generated $738.3 million in revenue, up 16.4% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $48.9 million, for a net margin of 6.6% versus a median of 16.4% in the prior 5 years. Gross margin was 52.3% (up from 43.3%) and operating margin 7.5%.
Diluted earnings per share came in at $0.86. Over the last 5 fiscal years, RGEN's revenue has grown at a 15.0% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Repligen income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 738.26M | 634.44M | 632.36M | 801.54M | 670.53M | 366.26M | 270.25M | 194.03M | 141.24M | 104.54M |
| Revenue growth (YoY) | +16.36% | +0.33% | -21.11% | +19.54% | +83.08% | +35.53% | +39.28% | +37.38% | +35.10% | +25.14% |
| Cost of Revenue | 352.01M | 359.79M | 353.92M | 345.83M | 279.28M | 156.63M | 119.10M | 86.53M | 67.05M | 47.12M |
| Gross Profit | 386.25M | 274.64M | 278.44M | 455.71M | 391.25M | 209.63M | 151.15M | 107.50M | 74.19M | 57.42M |
| Operating Expenses | 331.08M | 309.76M | 230.74M | 231.04M | 224.00M | 139.80M | 115.06M | 81.51M | 60.18M | 41.45M |
| Research & Development | 54.18M | 43.20M | 42.72M | 43.94M | 34.27M | 20.18M | 19.45M | 15.82M | 8.67M | 7.36M |
| Selling, General & Admin | 290.51M | 263.37M | 218.58M | 215.83M | 183.87M | 119.62M | 95.61M | 65.69M | 51.51M | 30.85M |
| Operating Income | 55.17M | -35.11M | 47.70M | 224.67M | 167.25M | 69.82M | 36.08M | 25.99M | 14.01M | 15.97M |
| Interest Expense | 21.51M | 20.73M | 1.95M | 1.16M | 11.28M | 10.77M | 9.29M | 6.71M | 6.44M | 3.77M |
| Other Income (Expense) | 7.22M | 8.08M | 9.00M | -5.53M | -13.71M | -10.61M | -9.93M | -4.55M | -6.76M | -4.28M |
| Pretax Income | 62.38M | -27.04M | 56.71M | 219.14M | 153.54M | 59.22M | 26.15M | 21.44M | 7.25M | 11.69M |
| Income Tax | 13.49M | -1.52M | 21.11M | 33.18M | 25.25M | -709.00K | 4.74M | 4.82M | -21.11M | 11.00K |
| Net Income | 48.89M | -25.51M | 35.60M | 185.96M | 128.29M | 59.93M | 21.41M | 16.62M | 28.35M | 11.68M |
| Net Income growth (YoY) | — | -171.68% | -80.86% | +44.95% | +114.08% | +179.88% | +28.85% | -41.39% | +142.73% | +25.00% |
| EPS (Basic) | 0.87 | -0.46 | 0.64 | 3.35 | 2.33 | 1.14 | 0.44 | 0.38 | 0.74 | 0.35 |
| EPS (Diluted) | 0.86 | -0.46 | 0.63 | 3.24 | 2.24 | 1.11 | 0.44 | 0.37 | 0.72 | 0.34 |
| Shares Outstanding (Basic) | 56.23K | 55.94K | 55.72K | 55.46K | 55.02K | 52.55K | 48.34M | 43.77M | 38.23M | 33.57K |
| Shares Outstanding (Diluted) | 56.56K | 55.94K | 56.38K | 57.45K | 57.26K | 53.89K | 49.21M | 45.47M | 39.15M | 34.10K |
| EBITDA | 133.91M | 34.56M | 116.26M | 275.65M | 205.70M | 96.89M | 56.95M | 41.77M | 24.51M | 21.31M |
| Gross Margin | 52.32% | 43.29% | 44.03% | 56.85% | 58.35% | 57.23% | 55.93% | 55.40% | 52.53% | 54.93% |
| Operating Margin | 7.47% | -5.53% | 7.54% | 28.03% | 24.94% | 19.06% | 13.35% | 13.39% | 9.92% | 15.28% |
| Net Margin | 6.62% | -4.02% | 5.63% | 23.20% | 19.13% | 16.36% | 7.92% | 8.56% | 20.07% | 11.17% |
This table shows 10 annual periods of Repligen's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow RGEN's reporting calendar. What is a income statement?